6-(4-carboxybutoxy)-3,4-dihydrocarbostyril | 58899-20-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-(4-carboxybutoxy)-3,4-dihydrocarbostyril
• 英文别名: 5-[(2-oxo-3,4-dihydro-1H-quinolin-6-yl)oxy]pentanoic acid
• CAS: 58899-20-0
• 化学式: C₁₄H₁₇NO₄
• mdl: MFCD10693422
• 分子量: 263.293
• InChiKey: VKAYMWDXNXBLRW-UHFFFAOYSA-N

物化性质

• 熔点：
  185-187 °C
• 沸点：
  543.7±50.0 °C(Predicted)
• 密度：
  1.233±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(4-carboxybutoxy)-3,4-dihydrocarbostyril 在 对甲苯磺酸 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,4-二氧六环 为溶剂， 反应 19.5h， 生成 ethyl 5-(2-oxo-1,2-dihydroquinolin-6-yl)oxypentanoate
  参考文献：
  名称：

  2-氧代喹啉衍生物作为血小板聚集抑制剂的研究。I.4-（2-氧代-1,2,3,4-四氢-6-喹啉基氧基）丁酸酯和相关化合物。

  摘要：

  合成并测试了许多烷基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯及相关化合物对体外血小板聚集的抑制活性。其中，乙基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯显示出最强的抑制活性。讨论了构效关系。

  DOI：

  10.1248/cpb.31.798
• 作为产物：
  描述：

  6-羟基-3,4-二氢-2(1H)-喹诺酮 在 sodium hydroxide 、 sodium ethanolate 、 sodium iodide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 44.0h， 生成 6-(4-carboxybutoxy)-3,4-dihydrocarbostyril
  参考文献：
  名称：

  2-氧代喹啉衍生物作为血小板聚集抑制剂的研究。I.4-（2-氧代-1,2,3,4-四氢-6-喹啉基氧基）丁酸酯和相关化合物。

  摘要：

  合成并测试了许多烷基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯及相关化合物对体外血小板聚集的抑制活性。其中，乙基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯显示出最强的抑制活性。讨论了构效关系。

  DOI：

  10.1248/cpb.31.798

文献信息

• Carbostyril derivatives
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04435404A1

  公开（公告）日：1984-03-06

  Novel carbostyril derivative and its salt represented by the general formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a phenyl-lower alkyl group; R.sup.2 is a hydrogen atom, a lower alkyl group or a group of the formula ##STR2## wherein A is a lower alkylene group; R.sup.3 is a lower alkyl group, a hydroxy lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkanoyloxy-lower alkyl group or a benzoyloxy-lower alkyl group; and R.sup.4 is a C.sub.3-10 -cycloalkyl group which may have at least one hydroxyl group as the substituent(s) in the cycloalkyl ring, a C.sub.3-10 -cycloalkyl-lower alkyl group, a phenyl group, a phenyl-lower alkyl group which may have at least one lower alkoxy group as the substituent(s) in the phenyl ring, a lower alkyl group which may have at least one hydroxyl group as the substituent(s), a heterocyclic ring residue or a lower alkyl group having one heterocyclic ring residue as the substituent; further, R.sup.3, R.sup.4 and the adjacent nitrogen atom, as well as with or without another nitrogen atom, may form a group of the formula ##STR3## (wherein R.sup.5 is a phenyl group, a C.sub.3-10 -cycloalkyl group or a phenyl-lower alkyl group; and B is a methine group or a nitrogen atom); the carbon-carbon bond between the 3- and 4-positions in the carbostyril skeleton is a single or double bond; the substituted position of the group of the formula ##STR4## is any one of 5-, 6-, 7- or 8-position in the carbostyril skeleton; when the group of the formula ##STR5## is substituted at 5-, 6-, 7- or 8-position in the carbostyril skeleton, then R.sup.2 is a hydrogen atom or a lower alkyl group; alternatively, when R.sup.2 is a group of the formula ##STR6## then 5-, 6-, 7- and 8-positions in the carbostyril skeleton are hydrogen atoms and are not substituted with groups of the formula ##STR7## and when R.sup.3 is a lower alkyl group, then R.sup.4 should be neither of a C.sub.3-10 -cycloalkyl group, a C.sub.3-10 -cycloalkyl-lower alkyl group nor a lower alkyl group, having effects for preventing and treating thrombosis and embolism.

  新型的羧基喹啉衍生物及其盐由通式（1）表示，其中R.sup.1是氢原子，低碳基团，低烯基团或苯基-低碳基团；R.sup.2是氢原子，低碳基团或式##STR2##的基团，其中A是低碳烷基团；R.sup.3是低碳基团，羟基低碳基团，低烷氧基-低碳基团，低烷酰氧基-低碳基团或苯甲酰氧基-低碳基团；R.sup.4是C.sub.3-10-环烷基团，该环烷基团可能至少有一个羟基作为环烷基环上的取代基，C.sub.3-10-环烷基-低碳基团，苯基，苯基-低碳基团，该苯基环上可能至少有一个低烷氧基作为取代基，低碳基，该低碳基可能至少有一个羟基作为取代基，杂环环残基或具有一个杂环环残基作为取代基的低碳基；此外，R.sup.3，R.sup.4和相邻的氮原子，以及有或没有另一个氮原子，可能形成式##STR3##的基团（其中R.sup.5是苯基，C.sub.3-10-环烷基团或苯基-低碳基团；B是亚甲基基团或氮原子）；羧基喹啉骨架中3-和4-位置之间的碳-碳键是单键或双键；式##STR4##的基团的取代位置是羧基喹啉骨架中的5-，6-，7-或8-位置中的任意一个；当式##STR5##的基团在羧基喹啉骨架的5-，6-，7-或8-位置取代时，R.sup.2是氢原子或低碳基团；或者，当R.sup.2是式##STR6##的基团时，羧基喹啉骨架的5-，6-，7-和8-位置是氢原子，并且未被式##STR7##的基团取代；当R.sup.3是低碳基团时，R.sup.4不应是C.sub.3-10-环烷基团，C.sub.3-10-环烷基-低碳基团或低碳基团，具有预防和治疗血栓形成和栓塞的作用。
• NISHI, TAKAO;YAMAMOTO, KATSUYOSHI;SHIMIZU, TAKEFUMI;KANBE, TOSHIMI;KIMURA+, CHEM. AND PHARM. BULL., 1983, 31, N 3, 798-810
  作者：NISHI, TAKAO、YAMAMOTO, KATSUYOSHI、SHIMIZU, TAKEFUMI、KANBE, TOSHIMI、KIMURA+

  DOI：——

  日期：——
• US4435404A
  申请人：——

  公开号：US4435404A

  公开（公告）日：1984-03-06
• Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyrates and related compounds.
  作者：TAKAO NISHI、KATSUYOSHI YAMAMOTO、TAKEFUMI SHIMIZU、TOSHIMI KANBE、YUKIO KIMURA、KAZUYUKI NAKAGAWA

  DOI：10.1248/cpb.31.798

  日期：——

  Many alkyl 4-(2-oxo-1, 2, 3, 4-tetrahydro-6-quinolyloxy) butyrates and related compounds were synthesized and tested for inhibitory activity against blood platelet aggregation in vitro. Among them, ethyl 4-(2-oxo-1, 2, 3, 4-tetrahydro-6-quinolyloxy) butyrate was found to have the most potent inhibitory activity. The structure-activity relationships are discussed.

  合成并测试了许多烷基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯及相关化合物对体外血小板聚集的抑制活性。其中，乙基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯显示出最强的抑制活性。讨论了构效关系。